Fig. 1From: A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinomaStudy Design. DLT – dose limiting toxicity; MTD – maximum tolerated doseBack to article page